US Stem Cell (US Stem Cell) Operating Income : $-1.72 Mil (TTM As of Dec. 2022)

View and export this data going back to 2008. Start your Free Trial

What is US Stem Cell Operating Income?

US Stem Cell's Operating Income for the three months ended in Dec. 2022 was $-0.37 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2022 was $-1.72 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. US Stem Cell's Operating Income for the three months ended in Dec. 2022 was $-0.37 Mil. US Stem Cell's Revenue for the three months ended in Dec. 2022 was $0.02 Mil. Therefore, US Stem Cell's Operating Margin % for the quarter that ended in Dec. 2022 was -1,870.00%.

US Stem Cell's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. US Stem Cell's annualized ROC % for the quarter that ended in Dec. 2022 was -17.33%. US Stem Cell's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was %.

US Stem Cell Operating Income Historical Data

The historical data trend for US Stem Cell's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

US Stem Cell Operating Income Chart

US Stem Cell Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Operating Income

Get a 7-Day Free Trial

-1.10

-3.42

-2.40

-2.14

-1.72

US Stem Cell Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Operating Income	Get a 7-Day Free Trial															-0.36	-0.52	-0.44	-0.40	-0.37

US Stem Cell Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.72 Mil.

US Stem Cell (OTCPK:USRM) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

US Stem Cell's annualized ROC % for the quarter that ended in Dec. 2022 is calculated as:

	ROC % (Q: Dec. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2022 )	+	Invested Capital (Q: Dec. 2022 ))	/ count )
=	-1.496 * ( 1 - 0% )	/	( (8.53	+	8.733)	/ 2 )
=	-1.496	/	8.6315
=	-17.33 %

where

	Invested Capital		(Q: Sep. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.172	-	5.098	-	( 0.03	-	max(0, 13.628	-	0.172	+	0.03	))
=	8.53

	Invested Capital		(Q: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.068	-	5.345	-	( 0.005	-	max(0, 14.078	-	0.068	+	0.005	))
=	8.733

Note: The Operating Income data used here is four times the quarterly (Dec. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

US Stem Cell's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2022 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2022 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2022		Q: Dec. 2022
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.5	/	( ( (0 + max(-5.424, 0))	+	(0 + max(-5.75, 0)) )	/	2 )
=	-1.5	/	( ( 0	+	0 )	/	2 )
=	-1.5	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Sep. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.003	+	0.001	+	0.138)	-	(5.098	+	0.003	+	0.465)
=	-5.424

	Working Capital		(Q: Dec. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.004	+	0.001	+	0.058)	-	(5.345	+	0.003	+	0.465)
=	-5.75

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2022) EBIT data.

3. Operating Income is also linked to Operating Margin %:

US Stem Cell's Operating Margin % for the quarter that ended in Dec. 2022 is calculated as:

Operating Margin %	=	Operating Income (Q: Dec. 2022 )	/	Revenue (Q: Dec. 2022 )
	=	-0.374	/	0.02
	=	-1,870.00 %

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

US Stem Cell Operating Income Related Terms

Thank you for viewing the detailed overview of US Stem Cell's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

US Stem Cell (US Stem Cell) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » US Stem Cell Inc (OTCPK:USRM) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323

Website

http://www.us-stemcell.com

US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.

Executives

Murphy William P Jr	director	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Gregory Knutson	director	14855 ABERDEN STREET NE, HAM LAKE MN 55304
Mark P Borman	director	5240 WASHBURN AVENUE SOUTH, MINNEAPOLIS MN 55410
Charles A Hart	director	19345 RHINESTONE STREET NW, ANOKA MN 55303
Sheldon T. Anderson	director	1121 CRANDON BLVD., APT. D-103, KEY BISCAYNE FL 33149
Kristin C Comella	officer: Chief Science Officer	1310 LEEWARD WAY, WESTON FL 33327
A Jones Lee	director	54 LOCKE LAKE RD, FRIDLEY MN 55432
Karl Groth	director	1160 FIFTH AVENUE, SUITE 207, NEW YORK NY 10029
Matthew J Fendrich	officer: Vice President,Sales&Marketing	482 PEACOCK LANE SOUTH, JUPITER FL 33458
Alan P Timmins	director	1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Bruce C Carson	director	11850 COTTONWOOD STREET NW, COON RAPIDS MN 55448
Howard J Leonhardt	director, 10 percent owner, officer: Executive Chairman & CTO	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Bromley R Scott	officer: VP of Public Relations	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Richard Iii Spencer	director	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Mike Tomas	director	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325